Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-frequency pembrolizumab for advanced non-small cell lung cancer
ISRCTN70247820Phase 3Recruiting
- Sponsor
- Imperial College London
- Start
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Imperial College London. Primary endpoint: Overall survival at 2 years. Started Jun 2022; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN70247820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN70247820.